ArticleJournal of perinatology : official journal of the California Perinatal Association2025
Navigating parental hesitancy in public health: the case for RSV immunization in newborns.
Article in Journal of perinatology : official journal of the California Perinatal Association, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- RSV Prophylaxis in Neonates: Implementation and Parental Acceptance during the First RSV Season in Germany.Geburtshilfe und Frauenheilkunde · 2026Article
- Review
- Burden of RSV-Associated Inpatient Care and Emergency Service Utilization in Two German Pediatric Centers Across Six Seasons Including the First Nirsevimab Year.Children (Basel, Switzerland) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Respiratory syncytial virus (RSV) poses a significant risk to newborns, particularly during the first months of life, and remains a leading cause of pediatric hospitalization in Germany. Despite the approval of innovative immunoprophylaxis methods like nirsevimab, parental hesitancy persists, driven by knowledge gaps and concerns about safety. This study assesses the healthcare burden of RSV during the 2022/2023 and 2023/2024 seasons and explores parental perspectives on immunization just prior to the widespread availability of nirsevimab in late 2024. Data revealed a significant hospital burden, including rising intensive care admissions requiring respiratory support. A survey conducted in two Bavarian maternity wards found that while 78% of parents were aware of RSV, only 53% supported postnatal immunization. These findings highlight the groundbreaking potential of RSV immunization and underscore the urgent need for targeted communication strategies to address parental concerns to ensure successful implementation of these programs.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.